Radiosynthesis and bioimaging of the tuberculosis chemotherapeutics isoniazid, rifampicin and pyrazinamide in baboons

Journal of Medicinal Chemistry

Volumn 53, Issue 7, 2010, Pages 2882-2891

  Liu, Li ^a   Xu, Youwen ^b   Shea, Colleen ^b   Fowler, Joanna S ^b   Hooker, Jacob M ^b,c   Tonge, Peter J ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b BROOKHAVEN NATIONAL LABORATORY   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 11; DRUG METABOLITE; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ANIMAL EXPERIMENT; ARTICLE; BABOON; BACTERIAL GROWTH; BLADDER; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG SYNTHESIS; GALLBLADDER; ISOTOPE LABELING; LIVER; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NEUROIMAGING; NONHUMAN; PLASMA PROTEIN BINDING; POSITRON EMISSION TOMOGRAPHY; RADIOSYNTHESIS; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; BLOOD PROTEINS; BRAIN; CARBON RADIOISOTOPES; HUMANS; ISONIAZID; PAPIO; POSITRON-EMISSION TOMOGRAPHY; PYRAZINAMIDE; RIFAMPIN; THORAX; TISSUE DISTRIBUTION;

EID: 77950579860     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm901858n     Document Type: Article

References (45)

1. Muller, M.; dela Pena, A.; Derendorf, H. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue Antimicrob. Agents Chemother. 2004, 48, 1441 - 1453 (Pubitemid 38544345)
2. Langer, O.; Muller, M. Methods to assess tissue-specific distribution and metabolism of drugs Curr. Drug. Metab. 2004, 5, 463 - 481
3. Fischman, A. J.; Alpert, N. M.; Babich, J. W.; Rubin, R. H. The role of positron emission tomography in pharmacokinetic analysis Drug Metab. Rev. 1997, 29, 923 - 956
4. Bloom, B. R.; Murray, C. J. Tuberculosis: commentary on a reemergent killer Science 1992, 257, 1055 - 1064
5. Kochi, A. The global tuberculosis situation and the new control strategy of the World Health Organization Tubercle 1991, 72, 1 - 6
6. Rattan, A.; Kalia, A.; Ahmad, N. Multidrug-resistant Mycobacterium tuberculosis: molecular perspectives Emerg. Infect. Dis. 1998, 4, 195 - 209
7. Bass, J. B., Jr.; Farer, L. S.; Hopewell, P. C.; O'Brien, R.; Jacobs, R. F.; Ruben, F.; Snider, D. E., Jr.; Thornton, G. Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention Am. J. Respir. Crit. Care Med. 1994, 149, 1359 - 1374
8. American Thoracic Society. Medical Section of the American Lung Association: Treatment of tuberculosis and tuberculosis infection in adults and children. Am. Rev. Respir. Dis. 1986, 134, 355 - 363.
9. Thwaites, G.; Fisher, M.; Hemingway, C.; Scott, G.; Solomon, T.; Innes, J. British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children J. Infect. 2009, 59, 167 - 187
10. Thwaites, G. E.; Tran, T. H. Tuberculous meningitis: many questions, too few answers Lancet Neurol. 2005, 4, 160 - 170
11. Nau, R.; Sorgel, F.; Prange, H. W. Pharmacokinetic optimization of the treatment of bacterial central nervous system infections Clin. Pharmacokinet. 1998, 35, 223 - 246
12. C synthesis module Appl. Radiat. Isot. 2008, 66, 482 - 488
13. 11C-labelled benzamide compounds as potential tracers for poly(ADP-ribose) synthetase Appl. Radiat. Isot. 1994, 45, 707 - 714
14. Milic, D. R.; Opsenica, D. M.; Adnadevic, B.; Solaja, B. A. NaY zeolite: A useful catalyst for nitrile hydrolysis Molecules 2000, 5, 118 - 126
15. Elias, G.; Bauer, W. F. Hydrazine determination in sludge samples by high-performance liquid chromatography J. Sep. Sci. 2006, 29, 460 - 464
16. Woo, J.; Cheung, W.; Chan, R.; Chan, H. S.; Cheng, A.; Chan, K. In vitro protein binding characteristics of isoniazid, rifampicin, and pyrazinamide to whole plasma, albumin, and α-1-acid glycoprotein Clin. Biochem. 1996, 29, 175 - 177
17. Nguyen, D. T.; Guillarme, D.; Rudaz, S.; Veuthey, J. L. Validation of an ultra-fast UPLC-UV method for the separation of antituberculosis tablets J. Sep. Sci. 2008, 31, 1050 - 1056
18. Nau, R.; Prange, H. W.; Menck, S.; Kolenda, H.; Visser, K.; Seydel, J. K. Penetration of rifampicin into the cerebrospinal fluid of adults with uninflamed meninges J. Antimicrob. Chemother. 1992, 29, 719 - 724
19. 14-labelled rifampicin into primate peripheral nerve Experientia 1975, 31, 1068 - 1069
20. Mindermann, T.; Landolt, H.; Zimmerli, W.; Rajacic, Z.; Gratzl, O. Penetration of rifampicin into the brain tissue and cerebral extracellular space of rats J. Antimicrob. Chemother. 1993, 31, 731 - 737
21. Mindermann, T.; Zimmerli, W.; Gratzl, O. Rifampin concentrations in various compartments of the human brain: a novel method for determining drug levels in the cerebral extracellular space Antimicrob. Agents Chemother. 1998, 42, 2626 - 2629
22. Barclay, W. R.; Ebert, R. H.; Le Roy, G. V.; Manthei, R. W.; Roth, L. J. Distribution and excretion of radioactive isoniazid in tuberculous patients J. Am. Med. Assoc. 1953, 151, 1384 - 1388
23. Barling, R. W.; Selkon, J. B. The penetration of antibiotics into cerebrospinal fluid and brain tissue J. Antimicrob. Chemother. 1978, 4, 203 - 227
24. Rouse, D. A.; Li, Z.; Bai, G. H.; Morris, S. L. Characterization of the katG and inhA genes of isoniazid-resistant clinical isolates of Mycobacterium tuberculosis Antimicrob. Agents Chemother. 1995, 39, 2472 - 2477
25. 14 labeled isonicotinic acid hydrazide in normal mice Proc. Soc. Exp. Biol. Med. 1952, 81, 566 - 569
26. Barlow, C. F.; Schoolar, J. C.; Roth, L. J. Distribution of carbon-14 labeled isoniazid in brain Neurology 1957, 7, 820 - 824
27. Schoolar, J. C.; Barlow, C. F.; Roth, L. J. Autoradiography of carbon-14 labeled isoniazid in brain Proc. Soc. Exp. Biol. Med. 1956, 91, 347 - 349
28. Ellard, G. A.; Humphries, M. J.; Allen, B. W. Cerebrospinal fluid drug concentrations and the treatment of tuberculous meningitis Am. Rev. Respir. Dis. 1993, 148, 650 - 655
29. Forgan-Smith, R.; Ellard, G. A.; Newton, D.; Mitchison, D. A. Pyrazinamide and other drugs in tuberculous meningitis Lancet 1973, 2, 374
30. Wu, J.-W.; Shih, H.-H.; Wang, S.-C.; Tsai, T.-H. Determination and pharmacokinetic profile of pyrazinamide in rat blood, brain and bile using microdialysis coupled with high-performance liquid chromatography and verified by tandem mass spectrometry Anal. Chim. Acta 2004, 522, 231 - 239
31. Nitti, V.; Virgilio, R.; Patricolo, M. R.; Iuliano, A. Pharmacokinetic study of intravenous rifampicin Chemotherapy 1977, 23, 1 - 6
32. Furesz, S.; Scotti, R.; Pallanza, R.; Mapelli, E. Rifampicin: a new rifamycin. 3. Absorption, distribution, and elimination in man Arzneim. Forsch. 1967, 17, 534 - 537
33. 14C-rifampicin II. Accumulation in melanin-containing structures Acta Pharmacol. Toxicol. 1975, 36, 267 - 283
34. Verma, R. K.; Kaur, J.; Kumar, K.; Yadav, A. B.; Misra, A. Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice Antimicrob. Agents Chemother. 2008, 52, 3195 - 3201
35. Roohi, S.; Mushtaq, A.; Jehangir, M.; Malik, S. A. Direct labeling of isoniazid with technetium-99m for diagnosis of tuberculosis Radiochim. Acta 2006, 94, 147 - 152
36. Stottmeier, K. D.; Beam, R. E.; Kubica, G. P. The absorption and excretion of pyrazinamide. I. Preliminary study in laboratory animals and in man Am. Rev. Respir. Dis. 1968, 98, 70 - 74
37. Peloquin, C. A.; Jaresko, G. S.; Yong, C. L.; Keung, A. C.; Bulpitt, A. E.; Jelliffe, R. W. Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide Antimicrob. Agents Chemother. 1997, 41, 2670 - 2679
38. Lacroix, C.; Hoang, T. P.; Nouveau, J.; Guyonnaud, C.; Laine, G.; Duwoos, H.; Lafont, O. Pharmacokinetics of pyrazinamide and its metabolites in healthy subjects Eur. J. Clin. Pharmacol. 1989, 36, 395 - 400
39. Zhang, Y.; Heym, B.; Allen, B.; Young, D.; Cole, S. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis Nature 1992, 358, 591 - 593
40. Blanchard, J. S. Molecular mechanisms of drug resistance in Mycobacterium tuberculosis Annu. Rev. Biochem. 1996, 65, 215 - 239
41. Rawat, R.; Whitty, A.; Tonge, P. J. The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: adduct affinity and drug resistance Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 13881 - 13886
42. Yarbrough, L. R.; Wu, F. Y.; Wu, C. W. Molecular mechanism of the rifampicin-RNA polymerase interaction Biochemistry 1976, 15, 2669 - 2676
43. Mao, J.; Wang, Y.; Wan, B.; Kozikowski, A. P.; Franzblau, S. G. Design, synthesis, and pharmacological evaluation of mefloquine-based ligands as novel antituberculosis agents ChemMedChem 2007, 2, 1624 - 1630
44. Glamkowski, E. J.; Reitano, P. A.; Woodward, D. L. Synthesis of 3-(4-acylaminopiperazin-1-ylalkyl)indoles as potential antihypertensive agents J. Med. Chem. 1977, 20, 1485 - 1489
45. Loening, A. M.; Gambhir, S. S. AMIDE: a free software tool for multimodality medical image analysis Mol. Imaging 2003, 2, 131 - 137